CRHR1 receptor binding and lipophilicity of pyrrolopyrimidines, potential nonpeptide corticotropin-releasing hormone type 1 receptor antagonists

被引:39
作者
Hsin, LW
Tian, XR
Webster, EL
Coop, A
Caldwell, TM
Jacobson, AE
Chrousos, GP
Gold, PW
Habib, KE
Ayala, A
Eckelman, WC
Contoreggi, C
Rice, KC
机构
[1] NIDDKD, Med Chem Lab, NIH, Bethesda, MD 20892 USA
[2] NIMH, Clin Neuroendocrinol Branch, NIH, Bethesda, MD 20892 USA
[3] NICHHD, Pediat Endocrinol Sect, PREB, NIH, Bethesda, MD 20892 USA
[4] Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, Baltimore, MD 21201 USA
[5] NIH, PET Dept, Ctr Clin, Bethesda, MD 20892 USA
[6] NIDA, Mol Neurobiol Unit, NIH, Baltimore, MD 21224 USA
关键词
D O I
10.1016/S0968-0896(01)00261-9
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
A series of compounds related to N-butyl-N-ethyl[2,5,6-trimethyl-7-(2,4,6-trimethylphenyl)pyrrolo[2,3-d]pyrimidin-4-yl]amine (1, antalarmin, Fig. 1) have been prepared and evaluated for their CRHR1 binding affinity as the initial step in the development of selective high affinity hydrophilic nonpeptide corticotropin-releasing hormone type 1 receptor (CRHR1) antagonists. Calculated log P (Clog P) values were used to evaluate the rank order of hydrophilicity for these analogues. Introducing oxygenated functionalities (delta -hydroxy or bis-beta -ethereal) into 1 gave more hydrophilic compounds, which had good affinity for the receptor. Introducing an amino group or shortening the alkyl side chain was detrimental to CRHR1 affinity. The alcohol 4-[ethyl[2,5,6-trimethyl-7-(2,4,6-trimethylphenyl)pyrrolo[2,3-d pyrimidin-4-yl]amino]butan-1-ol (3), bearing a terminal hydroxyl group on an N-alkyl side-chain, showed the highest CRHR1 binding affinity among these compounds (K-i=0.68 nM), and is one of the highest affinity CRHR1 ligands known. Compounds 3-5, and 8, which are likely to be less lipophilic than 1, have high CRHR1 affinity and may be valuable probes to further study the CRH system. (C) 2001 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:175 / 183
页数:9
相关论文
共 50 条
[21]   The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety [J].
Holsboer, F .
JOURNAL OF PSYCHIATRIC RESEARCH, 1999, 33 (03) :181-214
[22]   Synthesis and biological activity of fluoro-substituted pyrrolo[2,3-d]pyrimidines:: The development of potential positron emission tomography imaging agents for the corticotropin-releasing hormone type 1 receptor [J].
Hsin, LW ;
Webster, EL ;
Chrousos, GP ;
Gold, PW ;
Eckelman, WC ;
Contoreggi, C ;
Rice, KC .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2000, 10 (08) :707-710
[23]  
Hsin LW, 2000, J LABELLED COMPD RAD, V43, P899, DOI 10.1002/1099-1344(200008)43:9<899::AID-JLCR375>3.3.CO
[24]  
2-E
[25]  
IRWIN M R, 1987, Brain Behavior and Immunity, V1, P81, DOI 10.1016/0889-1591(87)90009-2
[26]   A SAUVAGINE CORTICOTROPIN-RELEASING FACTOR-RECEPTOR EXPRESSED IN HEART AND SKELETAL-MUSCLE [J].
KISHIMOTO, T ;
PEARSE, RV ;
LIN, CJR ;
ROSENFELD, MG .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (04) :1108-1112
[27]  
KOOB GF, 1993, P CIBA FDN S, V172, P277
[28]   Cloning and characterization of the human corticotropin-releasing factor-2 receptor complementary deoxyribonucleic acid [J].
Liaw, CW ;
Lovenberg, TW ;
Barry, G ;
Oltersdorf, T ;
Grigoriadis, DE ;
DESouza, EB .
ENDOCRINOLOGY, 1996, 137 (01) :72-77
[29]   CLONING AND CHARACTERIZATION OF A FUNCTIONALLY DISTINCT CORTICOTROPIN-RELEASING FACTOR-RECEPTOR SUBTYPE FROM RAT-BRAIN [J].
LOVENBERG, TW ;
LIAW, CW ;
GRIGORIADIS, DE ;
CLEVENGER, W ;
CHALMERS, DT ;
DESOUZA, EB ;
OLTERSDORF, T .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (03) :836-840
[30]   A non peptidic corticotropin releasing factor receptor antagonist attenuates fever and exhibits anxiolytic-like activity [J].
Lundkvist, J ;
Chai, Z ;
Teheranian, R ;
Hasanvan, H ;
Bartfai, T ;
Jenck, F ;
Widmer, U ;
Moreau, JL .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1996, 309 (02) :195-200